Research Update
Are We Missing a Potentially Reversible Contributor to Cognitive Impairment?
Susan L. Siegfreid, MD. Dr. Siegfreid has no financial relationships with companies related to this material.
Items Tagged with 'liver disease'
ARTICLES
EXPERT Q&A
Psychiatric Issues in Organ Transplantation
Paula C. Zimbrean, MD, FAPA, FACLP
Associate professor of psychiatry and surgery (transplant), Yale University School of Medicine; Chair, Transplant Psychiatry Special Interest Group, Academy of Consultation Psychiatry. New Haven, CT.
Dr. Zimbrean has consulted for Ultragenyx and Vivet Therapeutics, and has consulted and advised for Alexion. Relevant financial relationships listed for the author have been mitigated.
Carlat Total Access Subscriptions: Get access to every article on the website.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
Recommended
